By Fineline Cube 
Shanghai-based Cathay Biotech Inc. (SHA: 688065) has announced plans to raise RMB 6.6 billion (USD 901 million) through a private placement of 153,595,531 shares at RMB 42.97 (USD 5.86) per share. This significant capital raise is aimed at enhancing the company’s capabilities in the research, development, manufacturing, and sales of biobased materials.
Company Overview and Technology
Cathay Biotech is a leading supplier of bio-manufactured long-chain diacids and is engaged in the research and development, manufacturing, and sales of biobased materials. The company utilizes synthetic biology and other advanced disciplines to drive innovation in bio-manufacturing technology. A notable achievement in 2023 was the successful verification of a groundbreaking one-step bio-based high-temperature polyamide preparation method on a 5,000-ton pilot line.
Strategic Partnership with China Merchants Group
In July 2023, Cathay Biotech entered into a partnership with China Merchants Group (CMG), an important state-owned backbone enterprise directly managed by the central government. The collaboration was further intensified in September of the same year, marking a strategic move to expand Cathay Biotech’s market reach and enhance its technological capabilities.
Strategic Implications
The private placement plan and the partnership with CMG underscore Cathay Biotech’s commitment to advancing in the field of synthetic biology. The capital raised will be instrumental in accelerating the development and commercialization of innovative bio-based materials, positioning the company to meet growing market demands and contribute to the global shift towards sustainable materials. This strategic initiative is expected to enhance Cathay Biotech’s competitive edge and drive long-term growth in the biotechnology sector.-Fineline Info & Tech